A comprehensive comparison of these incretin-based research peptides, examining their receptor profiles, signaling mechanisms, and applications in preclinical metabolic research.
Part of the PeptidesATX Research Hub
The development of multi-receptor agonists has opened new avenues in metabolic research. GLP-2 and GLP-3 represent two distinct approaches to incretin-based investigation—dual and triple receptor agonism, respectively. Understanding their differences is essential for researchers designing studies in glucose metabolism, energy balance, and related pathways.
This comparison examines the structural, mechanistic, and practical research differences between these compounds, providing guidance for investigators selecting appropriate tools for their laboratory objectives.
GLP-2 targets two receptors (GLP-1 and GIP), while GLP-3 targets three receptors (GLP-1, GIP, and glucagon). This fundamental difference shapes their research applications and the biological questions each can address.
Both compounds engage incretin receptor systems but differ significantly in their receptor coverage. The table below summarizes their receptor activity profiles as reported in the developers' cell-based assays (Coskun et al., Mol Metab 2018 for GLP-2; Coskun et al., Cell Metab 2022 for GLP-3).
| Receptor Target | GLP-2 | GLP-3 |
|---|---|---|
| GLP-1 Receptor | ✓ Agonist activity | ✓ Agonist activity |
| GIP Receptor | ✓ Agonist activity | ✓ Agonist activity |
| Glucagon Receptor | ✗ No measurable activity reported (in vitro) | ✓ Agonist activity |
| Classification | Dual agonist | Triple agonist |
Relative potency at the shared receptors differs between the two: in the developers' assays GLP-2 shows greater potency at GIPR than at GLP-1R (Coskun 2018; Willard et al., JCI Insight 2020), and GLP-3 is most potent at GIPR, then GLP-1R, then the glucagon receptor (Coskun 2022). These are cell-assay values and do not by themselves predict effects in animal models.
Both GLP-3 and GLP-2 engage the glucagon-like peptide-1 receptor, a G protein-coupled receptor that has been extensively characterized in metabolic research.
For researchers focused primarily on GLP-1 signaling, both compounds provide relevant tools, though their additional receptor activities will influence overall metabolic effects observed in experimental models.
The glucose-dependent insulinotropic polypeptide receptor represents the second shared target between these compounds. GIPR has distinct tissue expression patterns and signaling characteristics compared to GLP-1R.
The dual incretin receptor engagement shared by both compounds distinguishes them from single-target GLP-1R agonists like GLP-1, offering expanded research applications.
The most significant distinction between GLP-3 and GLP-2 lies in glucagon receptor engagement. Only GLP-3 activates this pathway, creating unique research opportunities not available with dual agonists.
Traditional thinking positioned glucagon as counter-regulatory to insulin—raising glucose when needed. However, research interest has grown in glucagon's effects on energy expenditure and lipid metabolism. The hypothesis driving triple agonist development suggests that glucagon receptor activation may enhance metabolic effects beyond what dual agonism achieves, particularly in energy expenditure pathways.
Beyond receptor targeting, these compounds differ in their structural characteristics and pharmacological profiles.
| Property | GLP-2 | GLP-3 |
|---|---|---|
| Structure Basis | Single peptide engineered from the native GIP sequence (Coskun 2018) | Single peptide engineered for activity at all three receptors (Coskun 2022); backbone details are in the primary paper and not restated here |
| Half-life Extension | C20 fatty diacid moiety (albumin binding; FDA prescribing information) | Fatty diacid acylation (albumin binding; Coskun 2022) |
| CAS Number | 2023788-19-2 | 2381089-83-2 |
| Published literature | Larger published literature | Smaller published literature; phase 3 trials ongoing (human development status, for context only) |
The choice between GLP-3 and GLP-2 depends on specific research questions and experimental designs.
For detailed information on GLP-2 mechanisms and applications, see our GLP-2 Research Guide.
For comprehensive coverage of GLP-3's triple agonist profile, see our GLP-3 Research Guide.
Understanding how these compounds engage overlapping and distinct pathways helps researchers interpret experimental observations. The pathways below are those reported in the developers' cell assays and mouse studies (Coskun 2018; Coskun 2022); their relative contribution in any given model is a research question, not a settled fact.
Researchers should consider several factors when selecting between these compounds for specific investigations.
| Consideration | GLP-2 | GLP-3 |
|---|---|---|
| Pathway complexity | Two receptor systems to monitor | Three receptor systems to monitor |
| Control requirements | Standard dual agonist controls | May require additional glucagon-specific controls |
| Data interpretation | Established framework | Requires consideration of glucagon effects |
| Comparative studies | More published comparisons available | Novel comparisons possible |
As with all receptor-targeting compounds, species differences in receptor expression, binding affinities, and downstream signaling should inform experimental design and interpretation of results across different animal models.
Both compounds require adherence to research-grade quality standards for reliable experimental outcomes.
Researchers sourcing GLP-3 for comparative studies can review the GLP-3 product page for the current lot's certificate of analysis and the compound's verified identifiers.
The research landscape for these compounds continues to evolve as investigators explore their applications in metabolic science.
The decision between GLP-3 and GLP-2 ultimately depends on the specific research questions being addressed:
Both compounds represent valuable research tools in the metabolic peptide space, and their appropriate application depends on thoughtful alignment between compound characteristics and research objectives.
Sources: Coskun T, et al. Mol Metab. 2018;18:3–14 (GLP-2 in vitro characterisation and mouse studies; PubMed 30473097). Willard FS, et al. JCI Insight. 2020;5(17):e140532 (GLP-2 imbalanced, biased agonism in cell systems; PubMed 32730231). Coskun T, et al. Cell Metab. 2022;34(9):1234–1247 (GLP-3 in vitro receptor profile and obese-mouse studies; PubMed 35985340). GLP-2 structure and acylation: FDA prescribing information for the approved product (DailyMed). CAS numbers as printed on the PeptidesATX certificates of analysis.
The primary difference lies in receptor targeting: GLP-2 is a dual agonist activating GLP-1 and GIP receptors, while GLP-3 is a triple agonist that additionally targets glucagon receptors. This third receptor pathway distinguishes GLP-3 in metabolic research applications.
Researchers may select GLP-3 when investigating glucagon receptor signaling, energy expenditure mechanisms, or hepatic metabolism pathways. The triple agonist profile enables study of three-way receptor interactions that cannot be examined with dual agonists alone.
Yes, both compounds share GLP-1 and GIP receptor agonism. Research indicates both peptides engage these incretin receptors, though with potentially different binding affinities and signaling kinetics that remain subjects of ongoing investigation.
Glucagon receptor activation in GLP-3 research is studied for its effects on hepatic glucose production, energy expenditure, lipid oxidation, and thermogenesis. This pathway adds metabolic complexity not present in dual agonist compounds like GLP-2.
Access research-grade peptides and quality documentation for your laboratory investigations.
Shop GLP-3 Shop GLP-2 Certificates of AnalysisDisclaimer: These compounds are intended for laboratory research use only. They are not approved for human or veterinary use. All research must be conducted in accordance with applicable institutional and regulatory guidelines.